Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CN 1Q26 Innovative Drug Licensing Transactions Top USD60B: NMPA
Recommend 28 Positive 56 Negative 19 |
||||
|
||||
|
In 1Q26, China saw the transaction amount for licensing innovative drugs exceed USD60 billion, nearly half of the total for the entire year of 2025, according to a report by CCTV, citing data released by the National Medical Products Administration (NMPA). As of last Friday (27th), ten innovative drugs were greenlighted for sale this year, with two imported and eight domestically produced, a historic breakthrough in innovative drugs in China. This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
